clinical trial · NCT04868604
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Prostatic Neoplasms, Castration-Resistant64Cu-SAR-bisPSMA67Cu-SAR-bisPSMA
brief summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
started
Aug 11, 2021
primary completion
Sep 1, 2026
completion
Sep 1, 2026
last updated
Feb 5, 2026
official title
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol